Sheehan Panic Disorder Scale (SPS)

Home  >>  About Us  >>  David V. Sheehan MD, MBA  >>  Sheehan Scales and Structured Diagnostic Interviews  >>  Sheehan Panic Disorder Scale (SPS)

About the SPS
License Agreements for Use of the SPS
Training for the SPS
Translations and Linguistic Validation of the SPS
How to Cite the SPS


About the SPS

The Sheehan Panic Disorder Scale (SPS) assesses all of the core symptoms of Panic Disorder.  It can be used to assess and monitor these symptoms and behaviors over time.  It can be either patient-rated or clinician-rated.  It has 35 questions to assess a spectrum of symptoms and behaviors associated with Panic Disorder.  16 of these are core Panic Disorder symptoms.  The additional 19 questions assess symptoms and behaviors associated with the range of Panic Disorder clinical presentations.  The SPS uses a Likert-like response format ranging from “not at all” (0), “a little” (1), “moderately” (2), “markedly” (3), to “extremely” (4).  It is designed for use in clinical research studies and in clinical settings as a baseline and treatment outcome measure.  It is very sensitive to change and to treatment effects in double-blind, placebo-controlled studies.  This scale was previously named as either the Sheehan Clinician Rated Anxiety Scale (SCRAS) or the Sheehan Patient Rated Anxiety Scale (SPRAS).  The SPS, the SCRAS, and the SPRAS are identical in all but name.

For any scientific questions relating to the SPS, contact David V Sheehan MD MBA directly by email at: davidvsheehan@gmail.com

To view a copy of the SPS (click here)

To purchase and download a copy of the SPS (click here)


License Agreements for Use of the SPS

To license any version of the SPS for Use in a Study or for a Healthcare System:

  • To License the Paper / PDF Version for Use in a Research Study with Grants >$50,000 or for a Pharmaceutical Company – There is a charge of $1 per single administration (not per patient enrolled). The amount is payable in full before study initiation.  (click here to download this license agreement)
  • To License the Paper / PDF Version for Use in a Research Study with Grants <$50,000 – The SPS is available free of charge to undergraduate and graduate students and for academic colleagues for educational use and for use in a small study with less than $50,000 funding as long as it is properly cited and proper copyright attribution is given on any study documents.  (click here to download this license agreement)
  • To License the Paper / PDF Version for Use in a Healthcare System – There is a charge of $1 per single administration (not per patient). The amount is payable in full before use.  (click here to download this license agreement)
  • To LicenseComputerized / Electronic / Mobile or Tablet App Version for Use – contact akozsuch@nviewhealth.com

Training for the SPS

For information about training on the SPS, please contact: davidvsheehan@gmail.com


Translations and Linguistic Validation of the SPS

Mapi (http://www.mapigroup.com) is the official translation and linguistic validation service for all variants of the SPS.

MAPI Language Services is the exclusive coordinating center to ensure the production of consistent and conceptually equivalent translations of the SPS and to provide linguistic validation and certification of these translations and should be contacted directly for this purpose.  MAPI Language Services may charge its own usual fees for this work.

Marie-Sidonie Edieux

MAPI Research Trust

27 Rue de la Villette

69003 Lyon France

PROinformation@mapigroup.com

tel: +33 (0)4 72 13 66 67

fax: +33 (0)4 72 13 66 68/ :+33 (0)4 72 13 69 50


How to Cite the SPS

Use the following citations in referencing the SPS:

  1. Sheehan, D. V., Raj, A. B., Sheehan, K. H., & Soto, S. (1990). Is Buspirone Effective for Panic Disorder?. Journal of Clinical Psychopharmacology, 10(1), 3-11. PDF: http://journals.lww.com/psychopharmacology/Abstract/1990/02000/Is_Buspirone_Effective_for_Panic_Disorder_.2.aspx
  2. Sheehan, D. V., Raj, A. B., Sheehan, K. H., & Soto, S. (1988). The relative efficacy of buspirone, imipramine and placebo in panic disorder: a preliminary report. Pharmacology Biochemistry and Behavior, 29(4), 815-817. DOI: http://dx.doi.org/10.1016/0091-3057(88)90214-6
  3. Sheehan, D. V., Raj, A. B., Harnett‐Sheehan, K., Soto, S., & Knapp, E. (1993). The relative efficacy of high‐dose buspirone and alprazolam in the treatment of panic disorder: a double‐blind placebo‐controlled study. Acta Psychiatrica Scandinavica, 88(1), 1-11. DOI: http://dx.doi.org/10.1111/j.1600-0447.1993.tb03405.x
  4. Stein, M. B., Heuser, I. J., Juncos, J. L., & Uhde, T. W. (1990). Anxiety disorders in patients with Parkinson’s disease. Am J Psychiatry, 147(2), 217-220. DOI: http://dx.doi.org/10.1176/ajp.147.2.217
  5. Munjack, D. J., Bruns, J., Baltazar, P. L., Brown, R., Leonard, M., Nagy, R., Koek, R., Crocker, B., & Schafer, S. (1991). A pilot study of buspirone in the treatment of social phobia. Journal of Anxiety Disorders, 5(1), 87-98. DOI: http://dx.doi.org/10.1016/0887-6185(91)90019-P